Zenas adds experience to exec team

Inflammation and immunology (I&I) specialist Zenas BioPharma has named Jennifer Fox as its chief business officer and chief financial officer and Tanya Fischer as head of research and development and chief medical officer.

Bringing the duo in to these strategic and operational leadership positions Zenas for growth, as its monoclonal antibody obexelimab advances in late-stage clinical trials for multiple potential I&I indications.

"They will each be an invaluable addition to Zenas as we head into our next phase of growth, advancing multiple global programs in late-stage clinical development"The duo have been welcomed by Lonnie Moulder, founder and chief executive of Zenas.